Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Linagliptin”

Showing 20 of 0 results

Not applicableEnded earlyNCT04180813
What this trial is testing

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 85
Large-scale testing (Phase 3)Study completedNCT00800683
What this trial is testing

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 133
Early research (Phase 1)Study completedNCT02121509
What this trial is testing

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 74
Early research (Phase 1)Study completedNCT02173665
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 64
Large-scale testing (Phase 3)Study completedNCT00602472
What this trial is testing

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 1,058
Early research (Phase 1)Study completedNCT01947153
What this trial is testing

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Who this might be right for
Healthy
Boehringer Ingelheim 36
Early research (Phase 1)Study completedNCT02183584
What this trial is testing

Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 16
Early research (Phase 1)Study completedNCT02183467
What this trial is testing

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 44
Not applicableStudy completedNCT03648424
What this trial is testing

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Who this might be right for
Type 2 Diabetes Mellitus
Brigham and Women's Hospital 48,262
Large-scale testing (Phase 3)Study completedNCT00819091
What this trial is testing

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 245
Not applicableStudy completedNCT01677104
What this trial is testing

The Microvascular Function of GLP-1 and Its Analogues

Who this might be right for
Type 2 DiabetesObesity
Katarina Kos 63
Large-scale testing (Phase 3)Study completedNCT00954447
What this trial is testing

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 1,263
Post-approval studies (Phase 4)Study completedNCT01903070
What this trial is testing

Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Who this might be right for
Diabetes Mellitus
Profil Institut für Stoffwechselforschung GmbH 99
Large-scale testing (Phase 3)Study completedNCT01194830
What this trial is testing

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 234
Testing effectiveness (Phase 2)Study completedNCT00716092
What this trial is testing

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 121
Post-approval studies (Phase 4)Study completedNCT01969084
What this trial is testing

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Who this might be right for
Type II Diabetes Mellitus
Beth Israel Deaconess Medical Center 45
Not applicableStudy completedNCT01903356
What this trial is testing

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 724
Post-approval studies (Phase 4)Study completedNCT07247656
What this trial is testing

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Who this might be right for
Diabete Mellitus
Bahria University 200
Not applicableStudy completedNCT05313529
What this trial is testing

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Who this might be right for
Type 2 Diabetes MellitusMild Cognitive Impairment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 396
Large-scale testing (Phase 3)Study completedNCT00621140
What this trial is testing

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 503
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation